Whitefort Capital Management, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Whitefort Capital Management, LP reported 15 stock positions worth $317.7 million. Its top holding was Arbutus Biopharma (ABUS) at 20.2% of the portfolio, followed by Roivant Sciences (ROIV, 14.5%) and Bally's (BALY, 10.0%). Compared with Q3 2025, it opened 2 new positions, sold out of 1, added to 3 and reduced 4. The biggest buy was a new position in Sable Offshore (SOC) and the biggest sale Genworth Financial (GNW, shares −31%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001884931
- Portfolio Value
- $317.7M (Q4 2025)
- SEC Filing
- 0001013594-26-000254 ↗ filed Feb 17, 2026
Holdings Value
Holdings 15 stocks · $317.7M
| ABUS Arbutus Biopharma Corp. | 20.20% | 13,343,228 | $64.2M | No change |
| ROIV Roivant Sciences Ltd. | 14.48% | 2,120,000 | $46.0M | Reduce -40.0% |
| BALY Bally's Corp. | 9.99% | 1,921,372 | $31.7M | Add +43.0% |
| OABI Omniab Inc. | 8.28% | 14,223,658 | $26.3M | No change |
| JOYY Joyy Inc.-ADR | 8.26% | 404,944 | $26.2M | No change |
| TDAY USA Today Co. Inc. | 7.74% | 4,774,833 | $24.6M | Add +33.2% |
| GNW Genworth Financial Inc. | 7.22% | 2,540,301 | $22.9M | Reduce -31.4% |
| CDZI Cadiz Inc. | 7.04% | 3,986,822 | $22.4M | No change |
| SOC Sable Offshore Corp. | 5.43% | 1,910,793 | $17.2M | New |
| QURE Uniqure NV | 3.46% | 459,000 | $11.0M | New |
| SGRY Surgery Partners Inc. | 2.92% | 600,000 | $9.3M | Add +61.7% |
| LQDA Liquidia Corp. | 1.72% | 158,000 | $5.4M | Reduce -74.0% |
| OPK Opko Health Inc. | 1.69% | 4,253,340 | $5.4M | Reduce -13.2% |
| VATE Innovate Corp. | 1.06% | 743,000 | $3.4M | No change |
| KG Kestrel Group | 0.52% | 160,916 | $1.6M | No change |
Options reported separately and not counted above: MRNA puts ($29.5M), LQDA calls ($20.5M), GLD calls ($10.7M).
Other holdings (2): bonds, preferreds, convertibles and warrants · $12.8M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| OPKO HEALTH INC (OPK 3.75 01/15/29) | NOTE 3.750% 1/1 · principal | 9,350,000 | $12.5M | No change |
| NNAVW Nextnav Inc. | *W EXP 99/99/999 | 47,264 | $338K | No change |
Total filed on the 13F, all lines: $330.5M.
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
Options Activity Q3 2025 → Q4 2025
| MRNA Moderna Inc. | put | New | 1,000,000 | $29.5M |
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 40,000 | $26.6Mbefore exit |
| LQDA Liquidia Corp. | call | New | 594,700 | $20.5M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $391.6M | ABUS, ROIV, JOYY, BALY, GNW |
| Q1 2026 | 17 | $316.6M | ABUS, ROIV, JOYY, SOC, GNW |
| Q4 2025 | 15 | $317.7M | ABUS, ROIV, BALY, OABI, JOYY |
| Q3 2025 | 14 | $287.4M | ABUS, ROIV, GNW, JOYY, OABI |
| Q2 2025Amended | 14 | $239.0M | JOYY, ROIV, ABUS, GNW, OABI |
| Q1 2025 | 11 | $185.2M | ABUS, ROIV, JOYY, GNW, LQDA |
| Q4 2024 | 13 | $191.5M | ABUS, ROIV, LQDA, GNW, CDZI |
| Q3 2024 | 13 | $201.5M | ABUS, EDR, ROIV, JOYY, GNW |
| Q2 2024 | 16 | $143.4M | ABUS, ROIV, NN, GNW, GSL |
| Q1 2024 | 13 | $153.2M | GSL, ABUS, ROIV, LSXMK, GNW |